Globe Life (NYSE:GL) Releases FY 2026 Earnings Guidance

Globe Life (NYSE:GL) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 15.400-15.90 for the period, compared to the consensus estimate of 15.320. The company issued revenue guidance of -.

Globe Life Stock Performance

Shares of GL traded up $0.94 during mid-day trading on Thursday, hitting $152.19. 59,280 shares of the company’s stock were exchanged, compared to its average volume of 494,647. Globe Life has a 52 week low of $111.13 and a 52 week high of $153.00. The stock’s 50-day simple moving average is $143.31 and its 200-day simple moving average is $139.29. The firm has a market cap of $11.94 billion, a price-to-earnings ratio of 10.78 and a beta of 0.47. The company has a quick ratio of 0.07, a current ratio of 0.07 and a debt-to-equity ratio of 0.39.

Globe Life (NYSE:GL) last released its quarterly earnings results on Wednesday, April 22nd. The company reported $3.43 earnings per share for the quarter, missing the consensus estimate of $3.46 by ($0.03). Globe Life had a return on equity of 21.30% and a net margin of 19.37%.The firm had revenue of $1.56 billion for the quarter, compared to the consensus estimate of $1.56 billion. During the same quarter last year, the firm posted $3.07 earnings per share. The business’s revenue for the quarter was up 5.3% on a year-over-year basis. Globe Life has set its FY 2026 guidance at 15.400-15.90 EPS. On average, equities research analysts expect that Globe Life will post 15.27 EPS for the current year.

Globe Life Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Friday, April 3rd will be paid a $0.33 dividend. This represents a $1.32 annualized dividend and a yield of 0.9%. This is a boost from Globe Life’s previous quarterly dividend of $0.27. The ex-dividend date of this dividend is Thursday, April 2nd. Globe Life’s payout ratio is presently 9.38%.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on GL shares. Truist Financial boosted their price target on Globe Life from $158.00 to $180.00 and gave the company a “buy” rating in a research note on Friday, February 6th. Weiss Ratings raised Globe Life from a “hold (c+)” rating to a “buy (b)” rating in a research note on Monday, April 13th. Piper Sandler raised Globe Life to a “strong-buy” rating in a research note on Thursday, April 2nd. Wells Fargo & Company upped their price target on Globe Life from $171.00 to $172.00 and gave the stock an “overweight” rating in a research note on Friday, April 10th. Finally, Keefe, Bruyette & Woods reaffirmed a “moderate buy” rating and set a $168.00 price target on shares of Globe Life in a research note on Thursday, March 26th. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, Globe Life presently has a consensus rating of “Buy” and an average target price of $172.11.

Insider Activity at Globe Life

In related news, CEO Frank M. Svoboda sold 12,500 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $144.78, for a total transaction of $1,809,750.00. Following the completion of the transaction, the chief executive officer owned 35,868 shares of the company’s stock, valued at approximately $5,192,969.04. The trade was a 25.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CMO Jennifer Allison Haworth sold 10,000 shares of the business’s stock in a transaction dated Thursday, February 12th. The stock was sold at an average price of $143.14, for a total value of $1,431,400.00. Following the transaction, the chief marketing officer directly owned 17,479 shares of the company’s stock, valued at $2,501,944.06. The trade was a 36.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 82,807 shares of company stock valued at $12,041,286 in the last quarter. 2.11% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Globe Life by 6.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,391 shares of the company’s stock worth $1,237,000 after purchasing an additional 607 shares in the last quarter. NewEdge Advisors LLC boosted its position in Globe Life by 368.1% during the first quarter. NewEdge Advisors LLC now owns 6,806 shares of the company’s stock valued at $897,000 after buying an additional 5,352 shares during the period. Goldman Sachs Group Inc. boosted its position in Globe Life by 11.5% during the first quarter. Goldman Sachs Group Inc. now owns 563,021 shares of the company’s stock valued at $74,161,000 after buying an additional 58,163 shares during the period. Empowered Funds LLC purchased a new stake in Globe Life during the first quarter valued at about $428,000. Finally, Focus Partners Wealth boosted its position in Globe Life by 8.3% during the first quarter. Focus Partners Wealth now owns 8,559 shares of the company’s stock valued at $1,127,000 after buying an additional 656 shares during the period. Hedge funds and other institutional investors own 81.61% of the company’s stock.

About Globe Life

Globe Life, traded on the NYSE under the symbol GL, is a U.S.-based insurance holding company that underwrites and distributes a range of life and supplemental health insurance products. Through its subsidiary brands—Globe Life, American Income Life, Liberty National Life, United American Insurance Company and Family Heritage Life—it offers term life, whole life, fixed annuities and supplemental health coverage designed to meet the needs of individuals and families across various socioeconomic segments.

The company’s product suite includes low-cost, easy-to-understand life insurance policies, accidental death and dismemberment coverage, hospital indemnity plans and specified disease insurance.